Clinical evaluation of Deferasirox for removal of cadmium ions in rat

Chelation of Thallium (III) in Rats Using Combined Deferasirox and Deferiprone Therapy

Thallium and its compounds are a class of highly toxic chemicals that cause wide-ranging symptoms such as gastrointestinal disturbances; polyneuritis; encephalopathy; tachycardia; skin eruptions; hepatic, renal, cardiac, and neurological toxicities; and have mutagenic and genotoxic effects. The present research aimed to evaluate the efficacy of the chelating agents deferasirox (DFX) and deferiprone (L1) in reducing serum and tissue thallium levels after the administration of thallium (III), according to two different dosing regimens, to several groups of Wistar rats for 60 days. It was hypothesized that the two chelators might be more efficient as a combined therapy than as monotherapies in removing thallium (III) from the rats' organs. The chelators were administered orally as either single or combined therapies for a period of 14 days. Serum and tissue thallium (III) and iron concentrations were determined by flame atomic absorption spectroscopy. Serum and tissue thallium (III) levels were significantly reduced by combined therapy with DFX and L1. Additionally, iron concentrations returned to normal levels and symptoms of toxicity decreased.

Deferasirox loaded on fumed silica nanoparticles used in cancer treatment

Fumed silica nanoparticles loaded with deferasirox are three and five times more cytotoxic than cisplatin and deferasirox against MDA-MB-23, respectively.

Deferasirox-coated iron oxide nanoparticles as a potential cytotoxic agent

Two broad strategies for the use of iron chelators in cancer treatment have been explored.

Monensin ameliorates cadmium-induced hepatic injury in mice, subjected to subacute cadmium intoxication

This study was designed to evaluate the potential application of monensin as an oral drug for the treatment of cadmium-induced hepatic dysfunction. The study was performed using ICR mouse model. Twenty-seven adult ICR male mice were divided into three groups of nine animals each: control (received distilled water and food ad libitum for 28 days); Cd-intoxicated (treated orally with 20 mg/kg b.w. Cd(II) acetate from the 1st to the 14th day of the experimental protocol); and monensin treated group (intoxicated with Cd(II) acetate as described for the Cd-intoxicated group followed by an oral treatment with 16 mg/kg b.w. tetraethylammonium salt of monensic acid for two weeks). The obtained results demonstrated that the treatment of Cd-intoxicated animals with monensin restored the liver weight/body weight index to normal values, decreased the concentration of the toxic metal ion by 50% compared to the Cd-treated controls, and recovered the homeostasis of Cu and Zn. Monensin reduced the activity of aspartate aminotransferase, alanine aminotrasnferase and alkaline phosphatase in the plasma of Cd-treated animals to the normal control levels and ameliorated the Cd-induced inflammation in the liver. Taken together, these data demonstrated that monensin could be an effective chelating agent for the treatment of Cd-induced hepatotoxicity.

Chelation of thallium by combining deferasirox and desferrioxamine in rats

The hypothesis that two known chelators deferasirox (4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid) and desferrioxamine (DFO) might be more efficient as combined treatment than as monotherapies in removing thallium from the body was tested in a new acute rat model. 7-week-old male Wistar rats received chelators: deferasirox (orally), DFO (intraperitoneal; i.p.), or deferasirox + DFO as 75 or 150 mg/kg dose half an hour after a single i.p. administration of 8 mg thallium/kg body weight in the form of chloride. Serum thallium concentration, urinary thallium, and iron excretions were determined by graphite furnace atomic absorption spectrometry. Both chelators were effective only at the higher dose level, while DFO was more effective than deferasirox in enhancing urinary thallium excretion, deferasirox was more effective than DFO in enhancing urinary iron excretion. In the combined treatment group, deferasirox did not increase the DFO effect on thallium and DFO did not increase the effect of deferasirox on iron elimination. Our results support the usefulness of this animal model for preliminary in vivo testing of thallium chelators. Urinary values were more useful because of the high variability of serum results.

Effects of cadmium and monensin on spleen of mice, subjected to subacute cadmium intoxication

This study investigated the effects of cadmium (Cd) and monensin on spleen function in mice, subjected to subacute Cd-intoxication. Adult male ICR mice were divided into three groups (n = 6 per group) as follows: control group (received distilled water and food ad libitum); Cd-treated (20 mg/kg/b.w./day Cd(II) acetate for the first 2 weeks of the experimental protocol); monensin-treated mice (20 mg/kg/day Cd(II) acetate for the first 2 weeks followed by treatment with 16 mg/kg b.w./day monensin from days 15 to 28. On day 29, mice were sacrificed under light ether anesthesia. Exposure to Cd induced an increase in spleen index (SI). The treatment of cd-intoxicated mice with monensin significantly reduced SI compared to Cd alone. The data from the atomic absorbption analysis of spleen revealed a significant Cd accumulation in Cd-treated mice compared to controls, accompanied by a significant depletion of Fe concentration up to 30%. The treatment of the Cd-administered mice with monensin resulted in a significant decrease of Cd in spleen by 50% compared to Cd alone. Fe recovery occured in spleen of monensin-treated mice. Histopathological analysis of spleen showed that Cd significantly decreased the number of megakaryocytes and disturbed extramedullary hematopoiesis. The number of megakaryocytes increased when monensin was added. The data in this study suggest that monensin was able to reduce the effects of Cd on hematopoesis in mice.

The tetraethylammonium salt of monensic acid-An antidote for subacute cadmium intoxication: a study using an ICR mouse model

In this study, the ability of the chelating agent monensic acid (administered as the tetraethylammonium salt) to reduce the cadmium (Cd) concentration in the kidneys, liver, heart, lungs, spleen and testes of Cd-intoxicated mice was investigated. Chelation therapy with the tetraethylammonium salt of monensic acid led to a significant decrease of the Cd concentration in all of the organs of the Cd-treated mice. This effect varied from 50% in the kidneys to 90% in the hearts of the sacrificed animals (compared to the Cd-treated controls). No redistribution of the toxic metal ions to the brain of the animals as a result of the detoxification with the chelating agent was observed. The detoxification of the animals with the antibiotic salt did not perturb the endogenous levels of copper (Cu) or zinc (Zn). The tetraethylammonium salt of monensic acid significantly ameliorated the Cd-induced total iron (Fe) depletion in the liver and spleen of Cd-treated mice. It also restored to control levels the values of transferrin-bound Fe and the total iron binding capacity (TIBC) of the plasma. These results imply that the tetraethylammonium salt of monensic acid could be an efficient antidote in cases of Cd-intoxication.

Removal of cadmium by combining deferasirox and desferrioxamine chelators in rats

An investigation was conducted to evaluate the ability of two chelators, deferasirox and desferrioxamine (DFO), in removing cadmium from biological system. The potential efficiency of those chelators were investigated after cadmium administration for 60 days following two dose levels of 20 and 40 mg/kg body weight daily to male rats. However, abnormalities were observed in clinical signs after cadmium administration, such as yellowish discoloration of hair, flaccid and hypotonic muscles, irritability, weakness and loss of weight. The hypothesis that the two chelators might be more efficient as combined therapy than single therapy in removing metal ions from the body was considered. In this way, two known chelators, deferasirox and DFO were chosen and tested in the acute rat model. The chelation therapy results show that deferasirox and DFO are able ?to remove cadmium ions from the body, while iron concentration returned to the normal level and symptoms are decreased.

Chelation of aluminum by combining deferasirox and deferiprone in rats

The hypothesis that two known chelators deferasirox and deferiprone (L1) might be more efficient as combined treatment than as single therapies in removing aluminum from the body was tested in a new acute rat model. Seven-week-old male Wistar rats received chelators: deferasirox (orally [p.o.]), L1 (p.o.) or deferasirox + L1 as 100 or 200 mg/kg dose half an hour after a single intraperitoneal administration of 6 mg Al/kg body weight in the form of chloride. Serum aluminum concentration, urinary aluminum and iron excretions were determined by graphite furnace atomic absorption spectrometry. Both chelators were effective only at the higher dose level. While deferasirox was more effective than L1 in enhancing urinary aluminum excretion, L1 was more effective than deferasirox in enhancing urinary iron excretion. In the combined treatment group, deferasirox did not increase the L1 effect on aluminum and L1 did not increase the effect of deferasirox on iron elimination. Our results support the usefulness of this animal model for preliminary in vivo testing of aluminum chelators. Urinary values were more useful due to the high variability of serum results.

Chelation of cadmium by combining deferasirox and deferiprone in rats

The present research aimed to characterize the potential efficiency of two chelators after cadmium administration for 60 days following two dose levels of 20 and 40 mg/kg body weight daily to male rats. However, the hypothesis that the two chelators might be more efficient as combined therapy than as single therapy in removing cadmium from the body was considered. In this way, two known chelators deferasirox and deferiprone (L1) were chosen and tested in the acute rat model. Two chelators were given orally as a single or combined therapy for the period of a week. Cadmium and iron concentrations in various tissues were determined by graphite furnace and flame atomic absorption spectrometry methods, respectively. The combined chelation therapy results show that Deferasirox and L1 are able to remove cadmium ions from the body while iron concentration returned to the normal level and symptoms are also decreased.

Removal of thallium by deferasirox in rats as biological model

The present research aimed to characterize the potential efficiency of deferasirox in removing thallium after its administration for 30 days following two dose levels of 20 and 160 μm of thallium (III) chloride to male Wistar rats every day. After thallium administration some abnormal clinical signs such as red staining around the eyes, greenish mottling on the liver, weakness, loss of hair and weight, were observed in animals. Deferasirox was given orally to different groups of rats for a period of one week immediately after thallium administration. After chelation therapy, animals were killed by exsanguination from the abdominal aorta, and then thallium and iron concentrations in various tissues were determined by standard addition method. The chelation therapy results showed that deferasirox was able to remove thallium ions from the body and clinical symptoms were also reduced.